Group Overview
Established in 1958, Qilu Pharmaceutical is now one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures and distributes both Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs). Qilu currently has 12 subsidiaries, 11 domestic manufacturing sites and over 3,8000 employees worldwide. Qilu ranks among Top 3 in Chinese pharmaceutical industry in 2024. Dedicated to offering high-quality & trustworthy medicines to the world and improving people‘s well-being, Qilu is vigorously exporting its products to over 110 countries and regions around the world.
We continue to strengthen our R & D capabilities to build a robust and diversified portfolio for a sustainable business. Qilu always maintains an innovative development strategy and is achieving its organic growth leveraging its robust pool of over 5,200 scientists spreading across 6 R & D centers based in the US (Seattle, Boston, San Francisco) and China (Shanghai, Jinan, Hainan). To date, Qilu has launched approximately 350 products with over 79 products “First-to-Launch” in China. The company has also fostered a robust pipeline including over 200 generic products, over 20 biosimilars and over 80 innovative products.
Qilu always commits itself to offering high-quality & trustworthy medicines to the world and improving people’s well-being. It is the first Chinese company to obtain both USFDA and EDQM approval for sterile APIs. Its FDFs and APIs have been approved by USFDA, EMA, TGA, MHRA, PMDA, etc.
Qilu maintains a robust and sustainable growth in global market while consistently foraying into new geographies to further fortify its position globally. With a well-established domestic and overseas sales network, Qilu’s footprints has been set across the world.
Message Online
Please provide your relevant information and requirements. We will contact you within 1–2 business days. Thank you for your trust and support!
WeChat Official Account